365 related articles for article (PubMed ID: 29848362)
1. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
[TBL] [Abstract][Full Text] [Related]
2. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
[TBL] [Abstract][Full Text] [Related]
3. PanDrugs2: prioritizing cancer therapies using integrated individual multi-omics data.
Jiménez-Santos MJ; Nogueira-Rodríguez A; Piñeiro-Yáñez E; López-Fernández H; García-Martín S; Gómez-Plana P; Reboiro-Jato M; Gómez-López G; Glez-Peña D; Al-Shahrour F
Nucleic Acids Res; 2023 Jul; 51(W1):W411-W418. PubMed ID: 37207338
[TBL] [Abstract][Full Text] [Related]
4. In Silico Drug Prescription for Targeting Cancer Patient Heterogeneity and Prediction of Clinical Outcome.
Piñeiro-Yáñez E; Jiménez-Santos MJ; Gómez-López G; Al-Shahrour F
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540260
[TBL] [Abstract][Full Text] [Related]
5. Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer.
Xu C; Nikolova O; Basom RS; Mitchell RM; Shaw R; Moser RD; Park H; Gurley KE; Kao MC; Green CL; Schaub FX; Diaz RL; Swan HA; Jang IS; Guinney J; Gadi VK; Margolin AA; Grandori C; Kemp CJ; Méndez E
Clin Cancer Res; 2018 Jun; 24(12):2828-2843. PubMed ID: 29599409
[No Abstract] [Full Text] [Related]
6. From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.
Perera-Bel J; Hutter B; Heining C; Bleckmann A; Fröhlich M; Fröhling S; Glimm H; Brors B; Beißbarth T
Genome Med; 2018 Mar; 10(1):18. PubMed ID: 29544535
[TBL] [Abstract][Full Text] [Related]
7. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
[TBL] [Abstract][Full Text] [Related]
8. Systematic Prioritization of Druggable Mutations in ∼5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
Zhao J; Cheng F; Wang Y; Arteaga CL; Zhao Z
Mol Cell Proteomics; 2016 Feb; 15(2):642-56. PubMed ID: 26657081
[TBL] [Abstract][Full Text] [Related]
9. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
10. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
11. Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective.
Perales-Patón J; Piñeiro-Yañez E; Tejero H; López-Casas PP; Hidalgo M; Gómez-López G; Al-Shahrour F
Public Health Genomics; 2017; 20(2):81-91. PubMed ID: 28858862
[TBL] [Abstract][Full Text] [Related]
12. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
[TBL] [Abstract][Full Text] [Related]
13. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
14. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
[TBL] [Abstract][Full Text] [Related]
15. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.
Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C
JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574
[TBL] [Abstract][Full Text] [Related]
16. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
[TBL] [Abstract][Full Text] [Related]
17. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
18. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
19. OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level.
Xu Q; Zhai JC; Huo CQ; Li Y; Dong XJ; Li DF; Huang RD; Shen C; Chang YJ; Zeng XL; Meng FL; Yang F; Zhang WL; Zhang SN; Zhou YM; Zhang Z
BMC Cancer; 2020 Aug; 20(1):740. PubMed ID: 32770988
[TBL] [Abstract][Full Text] [Related]
20. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]